According to the Star of Securities, Watson Biological (300142) answered the question that investors care about on the investor relationship platform on April 08.
Investor: It is learned that the company’s PCV13 pneumonia combined vaccine has officially started vaccination in Morocco, Thailand, Bangladesh, and Indonesia. How many countries have the company’s PCV13 pneumonia binding vaccine?
Watson Biological Director: Dear investor, hello!The company is in contact with many countries. Considering the market competitive environment and business confidentiality requirements, the company will disclose when specific countries have achieved substantial progress.Thanks!Kanpur Investment
Investor: It is learned that the company’s PCV13 pneumonia combined vaccine has been officially vaccinated in Thailand and Indonesia. Because Thailand and Indonesia are PIC/S member states. May I ask whether its GMP certification can simplify and accelerate more than 50 other PIC/S member states and S member countries andRegional pharmaceutical registration and listing process?
Watson Biological Director: Dear investor, hello!The company’s 13 -valent pneumonia combined vaccine through Thailand’s GMP certification is conducive to improving the recognition of the system with PIC/S member countriesJaipur Stock. The specific registration process needs to comprehensively consider factors such as regulations and policies of various countries.Thanks!
Investor: I learned that the company’s MRNA new crown vaccine RQ3033 has been reported in the third phase of clinical research. Will the company have a listing application for listing in Thailand, Indonesia, Morocco and other countries?Is there a needle or a primary liquid export plan?
Watson Biological Director: Dear investor, hello!For specific information on overseas registration and export of related products, please refer to the information disclosed by the company.Thanks!
Investor: Dear Director, Hello!Watson Bio announced the phase III clinical research report received the RQ3033 vaccine, and the third -phase experiment reached the preset goal.In July of last year, your company released the clinical effectiveness report of the same RQ3013 vaccine.Which MRNA vaccine is currently in the progress of listing approval?Hope to clearly explain!Thanks
Watson Biological Director: Dear investor, hello!At present, the company’s RQ3033 vaccine is actively applying for approval to be listed (including the listing conditions). The specific time needs to be based on the supervision department’s approval opinions.Thanks!
Investor: Hello, the secretary, the analysis of the 9 -price HPV head of the company’s 9 -price HPV is not over yet?Is the analysis of this project entrusted and cooperative suppliers or internal?Is the efficiency so slowGuoabong Investment? Is there any contract with the supplier contract to complete the time limit?
Watson Biological Director: Dear investor, hello!The company’s Phase III clinical trials compared with similar vaccines and similar vaccines are in the stage of data statistical analysis and writing clinical research reportsKanpur Wealth Management. In the future, the research and development work will be promoted in accordance with the requirements of regulations and the company’s business planning.For the specific progress, please refer to the company’s subsequent disclosure information.Thanks!
The above content is organized by the securities star based on public information, which is generated by algorithms and has nothing to do with the position of this site.The Star of the Securities strives but does not guarantee the accuracy, integrity, validity, timeliness, etc. of all or part of the information (including but not limited to text, video, audio, data, and charts). Please contact us if there are problems.This article is data finishing, and does not constitute any investment advice to you. Investment is riskyHyderabad Stocks. Please decide carefully.
Simla Investment